Use of corilagin in the preparation of a drug for treating and / or preventing human papillomavirus infection and related diseases, a pharmaceutical composition and a preparation method

The topical dosage form prepared by Corilagin directly downregulates the expression of HPV E6 and E7 oncogenic proteins, solving the problem of the lack of effective drugs to inhibit HPV oncogenic proteins in the existing technology, and achieving a widely applicable treatment and prevention effect for HPV infection.

CN122163627APending Publication Date: 2026-06-09JIANGSU SENRUIPU BIOPHARMACEUTICAL CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JIANGSU SENRUIPU BIOPHARMACEUTICAL CO LTD
Filing Date
2026-05-09
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Current technologies lack effective drugs that can directly inhibit the expression of human papillomavirus (HPV) E6 and E7 oncogenic proteins, especially structurally well-defined small molecule compounds for diseases caused by high-risk and low-risk HPV infections.

Method used

Using corilagin or its pharmaceutically acceptable salts, the expression of HPV E6 and/or E7 oncogenic proteins is downregulated through local administration, and the products are prepared into dosage forms such as gels, creams, suppositories, films, and lyophilized powders for the treatment and prevention of HPV infection-related diseases.

Benefits of technology

It directly downregulates the expression of HPV E6 and E7 oncogenic proteins, blocking the viral carcinogenic pathway. It is applicable to a variety of diseases caused by high-risk and low-risk HPV infections, providing a widely applicable and highly effective treatment and prevention method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122163627A_ABST
    Figure CN122163627A_ABST
Patent Text Reader

Abstract

This invention discloses a novel use of corilagin or a pharmaceutically acceptable salt thereof in the preparation of medicaments for the treatment and / or prevention of human papillomavirus (HPV) infection and related diseases. This invention is the first to discover and demonstrate that corilagin can downregulate the expression of HPV E6 and / or E7 oncogenic proteins, thereby inhibiting viral activity and blocking the malignant transformation process driven by the virus. Based on this original discovery, corilagin or a pharmaceutically acceptable salt thereof can be used to prepare medicaments or pharmaceutical compositions for the prevention and / or treatment of persistent HPV infection, reversal of cervical intraepithelial neoplasia, adjuvant therapy for cervical cancer, and treatment of other HPV-related diseases (including but not limited to oropharyngeal HPV infection, anal HPV infection, vulvar intraepithelial neoplasia, etc.), preferably prepared as a mucosal topical dosage form. This discovery provides a novel, structurally well-defined small molecule drug candidate for the prevention and treatment of HPV-related diseases.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Application of Corilagin in preparing anti-tumor drugs

    CN101879173B

  • MicroRNA for preventing and treating human papilloma virus infection and cervical carcinoma

    CN104560992A

  • A Terminalia chebula extract with anticancer effects and its effective fraction preparation method

    CN109453212B

  • Method for analyzing anti-cervical cancer action mechanism of corilagin based on network pharmacology and molecular docking

    CN113936811A

  • Composition and application thereof in tumor anti-lactylation

    CN119679806A